<DOC>
	<DOCNO>NCT01014208</DOCNO>
	<brief_summary>This study conduct compare efficacy safety ofatumumab addition salvage chemotherapy versus rituximab addition salvage chemotherapy CD20 positive DLBCL subject relapse , persistent disease , first-line treatment rituximab combine anthracycline-based chemotherapy regimen eligible ASCT .</brief_summary>
	<brief_title>Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed Autologous Stem Cell Transplant Relapsed Refractory Diffuse Large B Cell Lymphoma</brief_title>
	<detailed_description>As rituximab-based regimen become standard first-line treatment CD20 positive DLBCL , efficacy rituximab combine salvage chemotherapy second-line setting decrease need new therapy patient progress relapse first-line rituximab-based therapy . Replacement rituximab ofatumumab second-line setting , follow progression/relapse first-line rituximab-containing regimen , offer potential overcome relative complete rituximab resistance thus improve response rate , ability proceed consolidative HDT/ASCT , overall survival .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subjects CD20 positive DLBCL grade 3b follicular lymphoma ( FL ) original diagnosis . Refractory , relapse following , firstline treatment rituximab combine anthracycline anthracenedionebased chemotherapy define protocol . CT involvement 2 clearly demarcate lesions/ node long axis &gt; 1.5 cm short axis &gt; = 1.0cm 1 clearly demarcate lesion/ node long axis &gt; 2.0 cm short axis &gt; = 1.0 cm . Baseline FDGPET scan must demonstrate positive lesion compatible CT define anatomical tumor site . Age 18 yr old . ECOG performance status 0 , 1 2 . Eligible high dose chemotherapy ASCT . Resolution toxicity firstline therapy grade opinion investigator contraindicate study participation . Signed write informed consent . Previous cancer therapy lymphoma , exception firstline rituximab/ anthracycline anthracenedionebased chemotherapy , monotherapy rituximab prior combine firstline chemotherapy , maintenance therapy , radiotherapy limit field part firstline treatment plan . Any anticancer therapy , except limited field radiotherapy , within 2 week prior start study therapy . Planned postrandomization chronic glucocorticoid use ( limited acute use allow define protocol ) unless administer therapy mild COPD asthma . Clinically significant cardiac disease , active chronic infection , serious significant disease , cancer within last 5 year . History significant cerebrovascular disease . Prior treatment antiCD20 monoclonal antibody exception rituximab . Abnormal/ inadequate WBC count , liver , kidney function . Pregnant lactate woman female patient childbearing potential ( male patient partner ) willing use adequate contraception 1 year follow dose completion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>The All Ireland Cooperative Oncology Research Group</keyword>
	<keyword>GELTAMO</keyword>
	<keyword>National Cancer Research Institute Lymphoma Clinical Studies Group</keyword>
	<keyword>Genmab</keyword>
	<keyword>ofatumumab</keyword>
	<keyword>Japan Clinical Oncology Group</keyword>
	<keyword>Oncology</keyword>
	<keyword>Polish Lymphoma Research Group</keyword>
	<keyword>Salvage chemotherapy</keyword>
	<keyword>refractory</keyword>
	<keyword>HOVON</keyword>
	<keyword>DVD</keyword>
	<keyword>relapse</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>DHAP</keyword>
	<keyword>rituximab</keyword>
	<keyword>Autologous Stem Cell Transplant</keyword>
	<keyword>Dutch-Belgian Cooperative Trial Group Hematology-Oncology</keyword>
	<keyword>Grupo Espanol de Linfomas</keyword>
	<keyword>Nordic Lymphoma Group</keyword>
</DOC>